I am a man and non sufferer.
I am not an expert.
I am only trying to provoke thought based on various bits I have seen in my journeys over the last year. I wish I had time to really look at this area. At the moment I have my time fully used looking at fats diet and health which includes BC.
It is important to appreciate the ovaries are not the only source of oestrogen. The cells of the bodies are like mini production plants and one of the things many of those plants do is make oestrogen hormones etc. A trigger for that is the COX 2 pathway which is dependent on omega six derivatives.
Fat cells store hormones including oestrogen and I think I have seen it stated that they are the largest source of oestrogen in post menopausal women.
I cannot recall if I saved it but I recollect a trial where breast levels of oestrogen where higher than those in the body fat. This for me raises the question if on site eostrogen production in the breast is greater factor than that produces by the ovaries.
There is also significant evidence that the fat balance is intimately tied up with hormone and oestrogen production. I posted a trial in the Greek diet post which suggested that the levels of receptors dropped significantly (a factor of six?) in animals where omega six consumption was reduced.
http://www.her2support.org/vbulletin...ad.php?t=24410
The trial below has a chapter Aromatase in breast cancer issues with a graph between cox 2 and aromatase which shows a straight line relationship. It is a complex read but worth struggling. It is also though provoking in that it underlines that much of what we eat contains nautual aromatse inhibitors, and the importance of local production in the breast.
If you go to the link and click on the blue icon you will get the full article.
I do not know if there is any merit / possibility in a watching breif in terms of monitoring oestradiol levels in the breast. I have seen reports where women have relied on natural aromatase inhibitors diet etc and monitored oestradoil. Try the "Annie Appleseed" BC site and search under oestradiol etc.
At a very personal and still confused level I still have a large number of question on the involvement of oestrogen. Oestrogen is a antioxidant it is reported so presumably helps guard against oxidative stress. Oxidative stress is what causes the degredation of the genes that is a factor leading to cancers. Omega six and three seem to control some of the mechanisms that make oestrogen. There is a growing recognition that some tumours are "stem" cell related. It is a whole very complex subject on its own. For me there is significant room for risk reduction through diet.
The young sufferer group report the highest disatisfaction levels. As you more than me will be aware the QOL issues are significant particularly in respect of fertility and femininity issues.
If I can find any stats I have saved I will post them. It would be worth trying to see what you can find.
It is also worth checking the stats on tamoxifen. I was surprised at the low additonal protection in percentage terms of tamoxifen as an addition over RT and boost in overall terms (which is not the same as for particular groups which could be better or worse). Tamoxifen also has some serious side effects for the few. Part of Tamoxifens action is intrvention in the fat pathways. Part of herceptins action is intervention in the fat pathways.
BUT all of this wittering is just that and things depend on your personal diagnosis aspirations, fears, outlook on life etc.
I can only suggest from my reading and as a male that you should do all the research and reading you can before making this decsion with your medical advisors.
This is a very though provoking link, and the MOJO link is worth checking out for a huge history of the female pespective on the subject, and between the lines the impact on their lives.
http://www.her2support.org/vbulletin...highlight=mojo
http://community.breastcancer.org/ub...page=2&fpart=1
http://www.her2support.org/vbulletin...ad.php?t=23891
I wish you the best with these hugely difficult personal decisions.
RB
http://www.ncbi.nlm.nih.gov/entrez/q...=pubmed_docsum
1: Endocr Rev. 2005 May;26(3):331-45. Epub 2005 Apr 6.Click here to read Links
Aromatase inhibitors in the treatment of breast cancer.
* Brueggemeier RW,
* Hackett JC,
* Diaz-Cruz ES.
College of Pharmacy, The Ohio State University, 500 West 12th Avenue, Columbus, Ohio 43210-1291, USA.
Brueggemeier.1@osu.edu
Estradiol, the most potent endogenous estrogen, is biosynthesized from androgens by the cytochrome P450 enzyme complex called aromatase. Aromatase is present in breast tissue, and intratumoral aromatase is the source of local estrogen production in breast cancer tissues. Inhibition of aromatase is an important approach for reducing growth-stimulatory effects of estrogens in estrogen-dependent breast cancer. Steroidal inhibitors that have been developed to date build upon the basic androstenedione nucleus and incorporate chemical substituents at varying positions on the steroid. Nonsteroidal aromatase inhibitors can be divided into three classes: aminoglutethimide-like molecules, imidazole/triazole derivatives, and flavonoid analogs. Mechanism-based aromatase inhibitors are steroidal inhibitors that mimic the substrate, are converted by the enzyme to a reactive intermediate, and result in the inactivation of aromatase. Both steroidal and nonsteroidal aromatase inhibitors have shown clinical efficacy in the treatment of breast cancer. The potent and selective third-generation aromatase inhibitors, anastrozole, letrozole, and exemestane, were introduced into the market as endocrine therapy in postmenopausal patients failing antiestrogen therapy alone or multiple hormonal therapies. These agents are currently approved as first-line therapy for the treatment of postmenopausal women with metastatic estrogen-dependent breast cancer. Several clinical studies of aromatase inhibitors are currently focusing on the use of these agents in the adjuvant setting for the treatment of early breast cancer. Use of an aromatase inhibitor as initial therapy or after treatment with tamoxifen is now recommended as adjuvant hormonal therapy for a postmenopausal woman with hormone-dependent breast cancer.
PMID: 15814851 [PubMed - indexed for MEDLINE]
Related Links
* Aromatase inhibitors: new endocrine treatment of breast cancer. [Semin Reprod Med. 2004] PMID: 15083379
* Aromatase, aromatase inhibitors, and breast cancer. [Am J Ther. 2001] PMID: 11550075
* Aromatase inhibitors in breast cancer therapy. [Expert Rev Anticancer Ther. 2002] PMID: 12113240
* Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms? [J Steroid Biochem Mol Biol. 2001] PMID: 11850229
* Use of aromatase inhibitors in breast carcinoma. [Endocr Relat Cancer. 1999] PMID: 10732791
* See all Related Article